RAC1 and neoplasm: Western blot analysis showed that Rac1 was down-regulated in tumors treated with dtACPPD/shRac1 (76.4% down-regulation, p < 0.01) (Figure 3F), suggesting the ideal tumor-targeting ability of the dtACPPD/shRac1nanoparticles.